Nov 2026· Frontiers in Immunology· Vol 17· 0 citations· 257 references
TL;DR
This review examines the major barriers to effective antitumor immunity within brain tumors, focusing on the immunosuppressive cellular and cytokine/chemokine molecular networks that shape the brain tumor immune microenvironment, the influence of tumor origin and subtype on immune composition, and the implications of these features for therapeutic responsiveness.
Abstract
Primary and metastatic brain tumors remain among the most challenging malignancies to treat, with limited therapeutic options and poor clinical outcomes despite substantial advances in cancer immunotherapy. Although immune checkpoint blockade (ICB) and other immunotherapies have transformed the treatment landscape for many cancers, they have demonstrated only limited efficacy in brain tumors. This limited responsiveness reflects the unique immune landscape of the central nervous system (CNS), which restricts immune cell infiltration and is further shaped by a highly immunosuppressive tumor immune microenvironment (TIME) that suppresses effective antitumor immunity. Consequently, therapeutic strategies capable of enhancing tumor immunogenicity while overcoming local immune suppression are urgently needed. One promising approach is the induction of immunogenic cell death (ICD), a form of regulated cell death that stimulates anti-tumor immunity through the release of danger-associated molecular patterns (DAMPs), tumor antigens, and inflammatory cytokines and chemokines that promote immune activation. However, the ability of ICD to generate durable antitumor responses within brain tumors is therefore likely influenced by the complex immunosuppressive networks that characterize the brain TIME. In this review, we examine the major barriers to effective antitumor immunity within brain tumors, focusing on the immunosuppressive cellular and cytokine/chemokine molecular networks that shape the brain tumor immune microenvironment, the influence of tumor origin and subtype on immune composition, and the implications of these features for therapeutic responsiveness. We then discuss how ICD may help overcome these barriers by enhancing antigen presentation, immune cell recruitment, and adaptive immune priming. We review the principal ICD-associated cell death modalities, including ferroptosis, necroptosis, and pyroptosis, and summarize current therapeutic approaches capable of inducing these pathways in brain tumors, including radiotherapy, chemotherapy, targeted therapies, oncolytic viruses, and emerging nanomedicine-based strategies. Finally, we highlight clinical and preclinical evidence supporting ICD-relevant therapeutic approaches across glioblastoma (GBM) and brain metastases and discuss rational combination strategies may improve immune responsiveness and therapeutic outcomes in patients.
Tumor immunotherapy has demonstrated significant clinical value in various malignancies by activating the host antitumor immune response. However, its clinical benefits are still limited by factors such as insufficient tumor immunogenicity, an immunosuppressive tumor microenvironment (TME), and acquired drug resistance...
Rui-Jie Xu· Transactions on Materials, B...· 0 citations
Abstract Non-apoptotic cell death modalities shape the tumor immune microenvironment and treatment outcomes in hepatobiliary cancers. Ferroptosis could directly kill cancer cells and enhance antitumor immunity and immunotherapy efficacy, but it may also promote immunosuppression in some contexts. Cuproptosis could elim...
Glioblastoma (GBM) is the most lethal primary central nervous system malignancy, with intrinsic immunosuppressive traits severely limiting the efficacy of conventional and immunotherapeutic regimens. This paper systematically elaborates the core causes, multi-layered molecular and cellular mechanisms, and targeted ther...
Si-Yu Zhao· Theoretical and Natural Scie...· 0 citations
Pediatric high-grade gliomas are among the most lethal malignancies, characterized by aggressive growth, profound immunosuppression, and limited therapeutic options. Although immune checkpoint inhibitors have produced durable responses in several systemic cancers, their efficacy in neuro-oncology remains consistently...
S. Frederico, I. Raphael, ReidAnn E. Sever et al.· Neuro-Oncology· 0 citations
This review summarizes the main immunotherapeutic approaches currently investigated, including immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, and oncolytic viruses, and examines the key biological factors responsible for treatment resistance.
D. Slavkov, S. Troyanova-Slavkova· Cancer Immunology Connect· 0 citations
Cancer immunotherapy has revolutionized oncology by improving therapeutic specificity and efficacy, leading to major clinical successes. Among these approaches, chimeric antigen receptor (CAR-T) cell therapy has shown remarkable results in hematological malignancies. However, its effectiveness in solid tumors is limite...
N. Shirazi, Shahab Pashaei, Mobarakeh Ajam-Hosseini et al.· Experimental and molecular p...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.